HEC-169096

N/A

Report date: 2024/12/20 17:55:56
NME

Base Information

Drug NameHEC-169096
Drug Alias NameHEC-169096
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor RET inhibitors
TargetsTyrosine-protein kinase receptor RET
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungThyroid Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGuangdong Dongyangguang Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSunshine Lake Pharma Co LtdGuangdong Dongyangguang Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungThyroid Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A